SPOTLIGHT -
EP. 1: FDA Approval of Ribociclib for Metastatic Breast Cancer
EP. 2: CDK4/6 Inhibitors for HR+ Metastatic Breast Cancer
EP. 3: Choosing Therapy for HR+ Metastatic Breast Cancer
EP. 4: Emerging CDK4/6-Targeted Therapy for Breast Cancer
EP. 5: Endocrine Resistance in HR+ Metastatic Breast Cancer
EP. 6: Sequencing in Hormone-Driven Metastatic Breast Cancer
EP. 7: PI3K Inhibitors for HR+ Metastatic Breast Cancer
EP. 8: Adjuvant Therapy for HER2-Driven Breast Cancer
EP. 9: Extended Adjuvant Therapy for HER2-Positive Breast Cancer
EP. 10: APHINITY Trial in HER2+ Breast Cancer
EP. 11: Pending FDA Approval of Neratinib in HER2+ Breast Cancer
EP. 12: Adjuvant Therapy for High-Risk HER2+ Breast Cancer
EP. 13: Triple-Positive Metastatic Breast Cancer
EP. 14: Brain Metastases in HER2-Positive Breast Cancer
EP. 15: Metastatic Triple-Negative Breast Cancer
EP. 16: BRCA-Mutated Triple-Negative Breast Cancer
EP. 17: PARP Inhibitors for BRCA-Mutated TNBC
EP. 18: Immunotherapy for Triple-Negative Breast Cancer
EP. 19: Final Thoughts on Progress in Breast Cancer Research
EP. 20: Options With CDK4/6 in HR+ Metastatic Breast Cancer
EP. 21: Evolving Therapies in HR+ Metastatic Breast Cancer
Further Understanding of Immune Mechanisms in Tumor Microenvironment Is Key to Advancing Immunotherapy in Solid Tumors
Navigating Systemic Therapy for RCC: Balancing Risk Status and Response
ADCs, Novel Targets Represent Next Wave of Treatment Advances in mCRPC
Precision Medicine in Prostate Cancer Care: Keeping Up With Evolving Guidance for Testing and Decision Making
